Literature DB >> 31149862

Aldehyde oxidase; new approaches to old problems.

Christine Beedham1.   

Abstract

Despite expanding knowledge on the structure and reactivity of human aldehyde oxidase (hAOX1) many drugs enter human studies only to be removed from further clinical trials due to aldehyde oxidase (AOX)-catalysed metabolism.In addition to oxidation of numerous N-heterocycles and aldehydes, hAOX1 is also important in amide hydrolysis and reductive reactions.This article reviews the evidence for hAOX1 polymorphism and other genetic factors which affect hAOX1 expression and which may lead to attenuated drug metabolism.Difficulties in the selection of appropriate in silico and in vitro models for predicting hAOX1 metabolism are considered in the context of its wide substrate specificity.

Entities:  

Keywords:  Aldehyde oxidase; N-heterocycles; aldehydes; genetic polymorphism; hydrolysis; oxidation; predictive models; reduction

Mesh:

Substances:

Year:  2019        PMID: 31149862     DOI: 10.1080/00498254.2019.1626029

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  5 in total

Review 1.  Pharmacogenomics of COVID-19 therapies.

Authors:  Takuto Takahashi; Jasmine A Luzum; Melanie R Nicol; Pamala A Jacobson
Journal:  NPJ Genom Med       Date:  2020-08-18       Impact factor: 8.617

2.  Synthesis of Deuterated Heterocycles with Me2NCD(OMe)2 and Evaluation of the Products for Metabolism by Aldehyde Oxidase.

Authors:  Chulho Choi; Anthony A Carlo; Ciarán N Cronin; Konghua Jing; Daniel W Kung; Jianhua Liu; Vincent M Lombardo; Abigail R Turco; Juxing Yin; Aijia Yu; Stephen W Wright
Journal:  ACS Med Chem Lett       Date:  2022-01-21       Impact factor: 4.345

3.  Pharmacokinetic/Pharmacodynamic Modelling of Allopurinol, its Active Metabolite Oxypurinol, and Biomarkers Hypoxanthine, Xanthine and Uric Acid in Hypoxic-Ischemic Encephalopathy Neonates.

Authors:  Wan-Yu Chu; Kim V Annink; Karel Allegaert; Alwin D R Huitema; A Laura Nijstad; Christian A Maiwald; Michael Schroth; Loubna El Bakkali; Frank van Bel; Manon J N L Benders; Mirjam M van Weissenbruch; Anja Hagen; Axel R Franz; Thomas P C Dorlo
Journal:  Clin Pharmacokinet       Date:  2021-10-07       Impact factor: 6.447

Review 4.  Pharmacogenomics of COVID-19 therapies.

Authors:  Takuto Takahashi; Jasmine A Luzum; Melanie R Nicol; Pamala A Jacobson
Journal:  NPJ Genom Med       Date:  2020-08-18       Impact factor: 8.617

Review 5.  ROCK Inhibition as Potential Target for Treatment of Pulmonary Hypertension.

Authors:  Tadeu L Montagnoli; Jaqueline S da Silva; Susumu Z Sudo; Aimeé D Santos; Gabriel F Gomide; Mauro P L de Sá; Gisele Zapata-Sudo
Journal:  Cells       Date:  2021-06-30       Impact factor: 7.666

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.